The primary objective of the current study is to investigate the influence of moderate to
severe renal impairment on the pharmacokinetics and safety of a single dose afatinib in
comparison to a control group with normal renal function.
The assessment of safety and tolerability will be an additional objective of this trial and
will be evaluated by descriptive statistics.